Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) shows significant upside potential with a mean price target of $36.25, indicating a 154.2% increase from the current price of $14.26 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $11.25, suggesting variability in analyst predictions. The lowest estimate is $15.00 (5.2% increase), while the highest is $48.00 (236.6% increase) [2]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MLYS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.6%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]. - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for potential price movement [14].

Group 1 - Alvotech (ALVO) shares have increased by 0.3% over the past four weeks, closing at $9.16, with a mean price target of $17.5 indicating a potential upside of 91.1% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $7, where the lowest estimate is $14.00 (52.8% increase) and the highest is $28.00 (205.7% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 6.3% over the last 30 days, with one estimate moving higher and no negative revisions [12] - Alvotech holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Core Viewpoint - On Holding (ONON) shares have shown a slight increase of 0.3% over the past four weeks, closing at $51.64, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $64.64, representing a 25.2% upside [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 22 short-term price targets with a standard deviation of $6.45, indicating variability among analysts; the lowest estimate is $50.00 (3.2% decline), while the highest is $75.00 (45.2% increase) [2][9]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9][10]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about ONON's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.6%, with two estimates moving higher and one lower [12]. - ONON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable predictor of the extent of ONON's gains, the implied direction of price movement appears to be a useful guide for investors [14].

Group 1 - Oneok Inc. (OKE) closed at $80.38, with a 0.7% gain over the past four weeks, and a mean price target of $103.35 suggests a 28.6% upside potential [1] - The mean estimate consists of 17 short-term price targets with a standard deviation of $15.23, indicating variability among analysts; the lowest estimate is $87.00 (8.2% increase), while the highest is $147.00 (82.9% increase) [2] - Analysts show increasing optimism about OKE's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 3.3% over the past month, with two estimates rising and one falling [12] - OKE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating potential upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Enovix Corporation (ENVX) has seen a significant stock price increase of 87.4% over the past four weeks, closing at $15.93, with analysts suggesting a potential upside to a mean price target of $25.92, indicating a 62.7% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate for ENVX comprises 12 short-term price targets with a standard deviation of $24.62, indicating variability among analysts. The lowest estimate is $9.00 (43.5% decline), while the highest is $100.00 (527.8% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that these targets rarely indicate actual stock price movements [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts regarding ENVX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] - ENVX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains for ENVX, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Cybin Inc. (CYBN) shows significant upside potential based on Wall Street analysts' short-term price targets, with a mean target of $78.8 indicating an 831.4% upside from the current price of $8.46 [1][2]. Price Targets and Estimates - The average price target consists of five estimates ranging from a low of $25.00 to a high of $150.00, with a standard deviation of $52.91, indicating variability among analysts [2]. - The lowest estimate suggests a 195.5% increase, while the highest points to a 1673.1% upside [2]. - A low standard deviation indicates a strong agreement among analysts regarding the price movement direction [9]. Analyst Sentiment and Earnings Estimates - Analysts exhibit strong agreement in revising CYBN's earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has risen by 3.1% over the past month, with two estimates increasing and no negative revisions [12]. - CYBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may not yield favorable returns [3][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

GeneDx Holdings Corp. (WGS) closed the last trading session at $80.47, gaining 24.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $101.53 indicates a 26.2% upside potential.The average comprises eight short-term price targets ranging from a low of $78.00 to a high of $115.00, with a standard deviation of $14.73. While the lowest estimate indicates a decline of 3.1% from the curr ...

Group 1 - VNET Group's shares have increased by 62.9% in the past four weeks, closing at $9.04, with a mean price target of $13.7 indicating a potential upside of 51.6% [1][2] - The mean estimate consists of seven short-term price targets with a standard deviation of $3.3, suggesting variability in analyst predictions; the lowest estimate is $10.00 (10.6% increase), while the highest is $20.00 (121.2% increase) [2][9] - Analysts show strong agreement on VNET's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for VNET has increased by 18.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - VNET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Group 1 - Marex Group PLC (MRX) closed at $39.49, with a mean price target of $51.56 indicating a 30.6% upside potential [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $6.62, ranging from a low of $36.00 (8.8% decline) to a high of $58.00 (46.9% increase) [2] - Analysts show strong agreement on MRX's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - Recent revisions in earnings estimates have been positive, with one estimate increasing and no negative revisions, leading to a 1% increase in the Zacks Consensus Estimate [12] - MRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be entirely reliable, it suggests a positive direction for MRX's price movement [14]

Group 1 - GH Research PLC (GHRS) closed at $15.99, with a 33.4% gain over the past four weeks, and a mean price target of $33.14 suggests a 107.3% upside potential [1] - The average price targets from analysts range from a low of $25.00 to a high of $40.00, indicating a potential increase of 56.4% to 150.2% from the current price level, with a standard deviation of $5.34 reflecting the variability of estimates [2] - Analysts show strong agreement on GHRS's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for GHRS's current year earnings has increased by 0.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - GHRS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]